Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioSphere's Sequitor guidewire

This article was originally published in Clinica

Executive Summary

BioSphere Medical has received US FDA 510(k) clearance to sell its Sequitor steerable guidewire, the newest addition to its line of embolic delivery products. The device is designed to facilitate the placement of catheters within the peripheral vasculature for various interventional procedures, including uterine fibroid embolisation and embolisation of hypervascularised tumours, such as liver tumours. The Rockland, Massachusetts firm expects to start shipping Sequitor in the US next month, when it also anticipates the product will be CE-marked and launched in Europe. BioSphere's principal focus is on uterine fibroid embolisation using its bioengineered microsphere technology.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT052035

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel